RxDoctor Payments Data

Brian Herbin, PA

Dermatology · Lincoln, NENPI 1295785525

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 30.0% of the total. That places this record below the midpoint for dermatology clinicians in NE, where the typical reported total is $2,089.

$1,826in general payments, 2019–2025

Across 104 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$548
  • AbbVie$313
  • Regeneron Healthcare Solutions, Inc.$224
  • Amgen$157
  • Novartis$98
  • Incyte Corporation$77
  • plus $409 from 13 others

What the payments were for

  • Food & beverage$1,818100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,826 in reported general payments places this provider in the 45th percentile of 68 dermatology providers in Nebraska.

See all dermatology providers in Nebraska

Medicare billing

Part B allowed, 2024
$213,493
Medicare patients
774
Services billed
4,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib12$89,547
OtezlaApremilast15$70,828
Clobetasol Propionate70$5,152
Triamcinolone Acetonide235$4,506
Imiquimod80$3,281
Minocycline Hcl83$2,643
Ketoconazole164$1,992
Mupirocin137$1,196
Clindamycin Phosphate43$1,017
Hydrocortisone136$869
Doxycycline Hyclate29$686
Terbinafine Hcl36$645
ValacyclovirValacyclovir Hcl14$524
Cephalexin56$478
Minoxidil36$434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$313$89,54712 claims
AmgenOtezla$157$70,82815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 68 dermatology providers in Nebraska.

Other dermatology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →